Pacific Biomarkers, Inc.’ Dr. Amar A. Sethi Honored by Pharmaceutical Executive Magazine as One of 30 Emerging Pharma Leaders of 2011

SEATTLE, WA--(Marketwire - June 28, 2011) - Pacific Biomarkers, Inc. (PBI) (OTCBB: PBMC), a provider of biomarker laboratory services to the pharmaceutical, biotechnology and diagnostics industries, is pleased to announce that Amar A. Sethi, MD, PhD, the Company’s Vice President of Research and Development, has been named one of 30 emerging pharma leaders in the June 2011 issue of Pharmaceutical Executive.

An article titled “Emerging Pharma Leaders 2011: Managing in the Era of Lean” includes profiles of 30 individuals. The profile for Dr. Sethi begins, “An academic background in clinical chemistry combined with a solid understanding of a key therapeutic segment -- lipid control medications -- set the foundation for Pacific Biomarkers vice president for research and development Dr. Amar Sethi’s career as a pathfinder in drug development.”

“We are very pleased and proud that Amar has been recognized with this distinguished honor. PBI is extremely fortunate to have a physician-scientist of Dr. Sethi’s stature as a valuable member of our team,” said Ron Helm, PBI’s Chairman and Chief Executive Officer. “PBI is committed to scientific and commercial excellence as our fundamental mission to develop novel biomarkers, and Dr. Sethi’s leadership in spearheading our efforts exemplifies this commitment.”

Mr. Helm concluded by saying: “Dr. Sethi’s leadership and experience will continue to play a major role in the company’s initiatives for the development of custom biomarker services and custom assay development in the rapidly growing clinical biomarker space.”

Dr. Sethi, along with the 29 others, will be honored at a dinner in October.

To read Dr. Sethi’s complete profile in the June issue of Pharmaceutical Executive, please visit the following link and scroll to the bottom of the page:
http://pharmexec.findpharma.com/pharmexec/article/articleDetail.jsp?id=726109&sk=&date=&%0A%09%09%09&pageID=7

About Pacific Biomarkers, Inc.

Established in 1989, PBI provides biomarker laboratory services and contract research services to support pharmaceutical and diagnostic manufacturers conducting human clinical trial research. The Company provides expert services in the areas of cardiovascular and musculoskeletal diseases, diabetes, obesity, and nutrition. The PBI laboratory is accredited by the College of American Pathologists, New York State, and the Lipid Standardization Program. PBI’s clients include many of the world’s largest pharmaceutical, biotech, and diagnostic companies. PBI also provides clinical biomarker services focusing on the emerging field of biomarker assay development and testing. Services include validating and performing custom assays for novel clinical biomarkers, immunogenicity testing, mass spectrometry, and multiplex testing.

PBI is headquartered in Seattle, Washington, and its common stock trades on the OTC Bulletin Board under the symbol “PBMC.”

For more information about PBI, visit the company’s website at www.pacbio.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This press release includes forward-looking statements including, but not limited to, the following: growth in revenues; results of business development activities; financial results; future growth; and growth and demand for our services, particularly our biomarker services. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ materially from those described in the forward-looking statements. These risks include, but are not limited to, the following: the Company’s ability to enter into contracts for its laboratory testing or biomarker services; client changes or early terminations of studies; the success of marketing and business development efforts, and competitive factors; the Company’s ability to manage growth; and other risks and uncertainties set forth in periodic filings with the U.S. Securities and Exchange Commission (including Form 10-K for the year ended June 30, 2010).